Pharmacogenomics Draft Guidance Needs Clarification, Industry Tells FDA
Executive Summary
Industry is pressing FDA to enhance the utility of its "companion guidance" on pharmacogenomic data submissions as the agency refines the draft document
You may also be interested in...
Panel to evaluate FDA pharmacogenomics paper
FDA will convene its Pharmaceutical Science and Clinical Pharmacology Advisory Committee March 18 to evaluate the agency's clinical pharmacogenomics concept paper. Industry is requesting that FDA clarify elements of the companion guidance, and the panel will discuss issues pertaining to collection of samples and applications of pharmacogenomics in clinical development (1"The Pink Sheet," Dec. 10, 2007, p. 18). The panel also will address qualitative clinical pharmacology. On March 19, the panel will discuss the renal impairment concept paper...
Panel to evaluate FDA pharmacogenomics paper
FDA will convene its Pharmaceutical Science and Clinical Pharmacology Advisory Committee March 18 to evaluate the agency's clinical pharmacogenomics concept paper. Industry is requesting that FDA clarify elements of the companion guidance, and the panel will discuss issues pertaining to collection of samples and applications of pharmacogenomics in clinical development (1"The Pink Sheet," Dec. 10, 2007, p. 18). The panel also will address qualitative clinical pharmacology. On March 19, the panel will discuss the renal impairment concept paper...
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says